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SUMMARY 
 
Our purpose is to determine the inflammatory changes in the airways of allergic 
paediatric asthma patients treated with omalizumab, measured by the percentage of  
eosinophils in induced sputum and exhaled nitric oxide (FENO). We observed a 
progressive and statistically significant decrease of eosinophil count in the induced 
sputum meanwhile FENO, although very sensible, was a less reproducible and thus a 
less reliable method to evaluate chronic airway inflammation in this population. 
Induced sputum seems to be a better method to monitor chronic inflammation and thus 
the response to chronic omalizumab treatment while FENO measurement would be 
more useful to monitor acute events preceding exacerbations. 
 
RESUM 
 
El nostre objectiu és determinar els canvis inflamatoris en la via aèria de pacients 
pediàtrics afectes d’asma al·lèrgica tractats amb omalizumab, mesurat pel percentatge 
d’eosinòfils en esput induït i la fracció d’òxid nítric exhalat (FENO). Hem observat una 
disminució progressiva i estadísticament significativa del percentatge d’eosinòfils en 
esput induït mentre que la FENO, tot i ser molt sensible, resulta ser un mètode menys 
reproductible i per tant menys fiable per avaluar la inflamació crònica de la via aèria 
d’aquesta població. L’esput induït sembla una millor tècnica per monitoritzar la 
inflamació crònica i així la resposta al tractament amb omalizumab. En canvi, la FENO 
sembla més útil per predir exacerbacions. 
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INTRODUCTION 
 
The prevalence of allergic diseases has progressively increased in the past decades. 
Asthma is one of the most common chronic diseases worldwide, affecting an estimated 
300 million individuals. The ISAAC study reported the prevalence in the paediatric 
population to be around 10%, affecting 9 million Americans < 18 (1). In our setting, the 
figure in the general population is around 3.5% (2). 
Asthma management is a costly business, accounting for around 1-2% of the total health 
care expenditure in developed economies (3). Developing economies are also likely to 
face increased demand (3). Poorly controlled asthma is expensive, and investment in 
prevention medication is likely to yield cost savings in emergency care (3-4).  
The incidence, morbidity and mortality of the condition have increased over the last 
fifty years despite the development of new drugs. Fewer than 1% of the asthmatic 
population are steroid-dependent, but these patients consume most of the time and 
resources (5). To address this situation, asthma units have been set up for severe chronic 
asthma and have proved effective and efficient (6). 
The consensus documents published by professional societies all support a stepwise 
therapeutic approach for asthma (3, 7-8). The update of the Global initiative for asthma 
treatment (GINA) report (3) in November 2006 offered for the first time an alternative 
to oral corticosteroids in patients included in step V (the most severe patient’s step). 
This drug is omalizumab, an anti-IgE blocking agent. To date, there is a huge 
experience on omalizumab effectiveness in adults (9), but in paediatric population, the 
information is fewer. Moreover, there is scarce information about the inflammatory 
response in paediatric asthma patients treated with omalizumab. Our aim was to study 
the changes the drug could cause in the airway inflammation in severe asthma patients.  
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MATERIAL AND METHODS 
 
Population. 
Patients were recruited from the out-patient clinic for asthma treatment of the paediatric 
service at our institution.  
The inclusion criteria were:  
1) Patients aged between 2 and 18 years.  
2) Severe asthma according to the GEMA guide. 
3) Positive prick test or in vitro reactivity (CAP) to at least one aeroallergen.  
The exclusion criteria were:  
1) Patient or patient’s relatives refusing treatment 
2) Hypersensitivity to omalizumab 
3) Patient unable to regularly attend the asthma unit for control and drug administration 
4) Previous anti-IgE treatment 
5) Patient’s relatives refusing  to sign the written informed consent 
 
Sample size: since this is one of the few studies including patients under 6 years treated 
with omalizumab, we could not calculate the number of patients needed for a post-hoc 
analysis. Following the experience in a large observational study in adult population (9), 
for statistical evaluation, we planned to have a minimum of 30 patients followed.   
 
Methods: 
Study design: Single-centre, prospective, open-label, observational interventional study.  
Setting: The study will be performed at the Paediatric Service of Corporació Parc Taulí 
(CPT) (Sabadell/Catalonia), a 760-bed university teaching hospital. 
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Treatment protocol: best standard care (BSC) following the recommendations of the 
GEMA included inhaled corticoids, inhaled long-acting beta-agonists (LABA) 
(salmeterol 50 µg bid), montelukast and oral methyl-prednisolone if needed. Prior to 
starting omalizumab treatment, patients underwent a run-in period of at least one month 
to assess the patients was correctly following the BSC established for him.  
The study was conducted between 2006 and 2012. 
 
Outcomes: the primary outcome of effectiveness was the decrease in sputum eosinophil 
count. The secondary outcome was to study the changes in patients’ FENO.  
The primary safety outcome was to estimate tolerance drug and the incidence of side-
effects.  
 
Instrumentation 
At entry we obtained from every patient: a total IgE concentration, specific IgE against 
the most relevant allergen, the percentage of eosinophils in a smear of induced sputum 
and the exhaled fraction of nitric oxide (FENO) (Niox Mino, Phadia). Induced sputum 
and NO were measured at the end of follow-up.  
 
Intervention: Omalizumab was administered once or twice a month in the outpatient 
unit of the paediatric service of our institution. Patients remained under observation for 
one hour after all injections. The dose was calculated according to the dosing tables 
published and accepted by the European Medical Agency (EMEA) (10). If the 
calculated dose exceeded the highest allowed dose, the maximum allowed dose was 
administered.   
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Side-effects.  
Patients were specifically asked about side-effects at each visit. They were also given 
the telephone number of the outpatient unit of the paediatric service to report any 
suspected side-effects. Immediate side-effects would have been detected at outpatient 
unit during the period of clinical observation. 
 
Statistical analysis. Descriptive statistics will include frequencies and percentages for 
categorical variables and means and standard deviations for continuous variables. 
Parametric (student’s t test for paired data) will be used to compare the initial and end, 
FENO and  sputum induced cell count. SPSS will be used for data compilation and 
analysis. A p-value < 0.05 will be considered statistically significant 
 
Informed consent. Written informed consent was obtained if age was under 6 years, 
since the treatment is only accepted by the international guidelines for older population. 
The IRB at our institution requires only oral informed consent from patients for the 
anonymous treatment of their data. The IRB of the hospital has accepted the study to be 
performed. 
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RESULTS 
 
Between 2006 and 2012, 31 patients with asthma were treated with omalizumab (15 
male -51.6%; 16 females -48,4%-). The age ranged between 6 -18 years. The follow-up 
of the patients was not uniform, ranging from 2 to 6 years.  
 
Total IgE concentration at entry:  668.89 (117.79) IU/mL.  
 
Specific IgE against the major antigen at entry: 42.15 (7.32) IU/mL; (22 house dust 
mite; 7 alternaria; 2 cladosporium).  
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
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Initial and end induced sputum: 6.26 (2.03) % Vs 2.47 (0.36) %; (p< 0.05).  
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Initial and end FENO values: 19.04 (1.98) ppb Vs 18.10 (2.11) ppb (p=NS). Three 
patients were excluded from the evaluation due to exaggerated values in the final NO 
measurement that preceded a severe exacerbation. 
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DISCUSSION 
 
The prevalence of allergic diseases has progressively increased in the past decades. 
Asthma is one of the most common chronic diseases worldwide, affecting an estimated 
300 million individuals. The ISAAC study reported the prevalence in the paediatric 
population to be around 10%, affecting 9 million Americans < 18 (1). In our setting, the 
figure in the general population is around 3.5% (2). 
The consensus documents published by professional societies all support a stepwise 
therapeutic approach for asthma (3, 7-8). However, patients who require frequent or 
continuous oral corticosteroid administration have received little attention. Due to the 
severe side-effects of steroids when administered over long periods or at high doses, 
considerable efforts have been devoted to the search for a possible corticosteroid 
sparing agent and many drugs have been assessed (12). The update of the Global 
initiative for asthma treatment (GINA) report
 
(3) in November 2006 offered for the first 
time an alternative to oral corticosteroids in patients included in step V (the most severe 
patient’s step). This drug is omalizumab, an anti-IgE blocking agent. So far, 
omalizumab has mainly been used in moderate and severe asthma patients to quantify 
the inhaled corticosteroids (10) rather than the oral steroid-sparing capacity 
The GINA advises the use of anti-IgE as an alternative or in addition to oral 
corticosteroids in step V patients and in uncontrolled patients with severe allergic 
disease and increased levels of IgE. In a naturalistic setting, omalizumab has shown and 
excellent tolerance and effectiveness in a population of patients with steroid-dependent 
asthma, the first study of its kind to date (9). Although the drug has been mainly used in 
adult population, to date there is already enough experience in paediatric population to 
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prescribe the drug. In any case anyway, there is a lack of parameters that allow the 
clinician when and how decrease or stop the treatment (13)  
It is well known nowadays that asthma is a chronic inflammatory disease of the airways 
caused by the interaction of several types of cells and molecules. The cells involved 
include mast cells, eosinophils, T-lymphocytes, macrophages and neutrophils. The 
inflammatory cascade is mediated by cytokines and interleukins. When an atopic 
individual is exposed to an antigen, the dendritic cells (specialized macrophages located 
in the organism’s epithelium) internalize it, process it and present it to a T lymphocyte, 
via the major histocompatibility complex. In this process the T lymphocyte develops a 
Th2 or a Th1 profile. When the type of antigen is an allergen, the lymphocyte 
differentiates into a Th2 cell able to produce IL-4 which in turn promotes the synthesis 
of IgE by the B lymphocytes (10).  
 
IgE-dependent inflammatory phenomena have been studied in depth and are recognized 
in atopic subjects (14). In these subjects, exposure to high concentrations of allergens, 
above all dust mites at early ages, leads to a high concentration of serum IgE, which 
favours the appearance of allergic symptoms. Omalizumab has been found to block 
99% of the circulating IgE in four hours (9). Nevertheless, the benefits of the treatment 
are slow to manifest themselves, and in some cases the patient may take several months 
to improve.  
Omalizumab offers some delayed benefits. Some studies have demonstrated its anti-
allergic and anti-inflammatory properties, such as the reduction in circulating and tissue 
eosinophils and, more recently, the increase in eosinophil apoptosis and the decrease in 
granulocyte macrophage colony stimulating factor (GM-CSF), IL-2 and Il-13 (14). 
Prussin et al’s (15) results demonstrated that anti-IgE therapy causes a rapid decrease in 
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dendritic cell surface FcεRI expression and established that IgE is an important 
regulator of FcεRI expression by dendritic cells.  
Omalizumab’s effect in treated patients is progressive, and for this reason the time to 
response is not uniform. IgE directly binds to and activates receptors present on 
eosinophils, neutrophils, and monocytes. Thus, the free IgE concentration may also be a 
key factor in patient control. Two aspects are involved in this process: the duration of 
the inflammatory process, and the triggering factor, that is, the free IgE (9) 
Though the regulation of IgE described above is found in atopic subjects, recent 
publications show that IgE may be produced by T lymphocytes in non-allergic subjects 
due to the presentation of the allergen through the mucosa. This IgE may bind to the 
high affinity receptors on the mast cells or basophils and produce the same type of 
inflammation as in the subjects considered allergic (10). The rationale for the use 
omalizumab in non-allergic patients is based in the relatively recent finding that IgE 
can be produced locally in mucosal tissue, without any increase in IgE levels in the 
blood, somewhat blurs the distinction between non-atopic and atopic diseases such as 
asthma (16)  
In any case, clinicians lack of reliable parameters to monitor drug response other than 
spirometry and/or patient’s clinical evaluation. The rationale of our study was that  the 
evaluation of  airway inflammation could offer some advantages to monitor drug 
response. In this way, we postulated that FENO as well as eosinophil count in induced 
sputum could be helpful parameters. We observed that the eosinophil count in induced 
sputum progressively decreased in treated patients, although the direct target of 
omalizumab is IgE. In other words, omalizumab showed an anti-eosinophil effect that 
could help to explain, at least partially the effect of the drug. FENO shows the airway 
inflammation in a cross sectional manner. It is influenced by many factors such as the 
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meteorological conditions, inhaled steroid treatment, that can acutely modify its airway 
concentration. Thus it is not surprising that this parameter is less reliable to monitor 
drug response in such a severe cohort of patients. 
Our study has several limitations, the most important being its uncontrolled nature. This 
means that we could not compare a treated group with a control group. However, this 
could in fact be considered as a strength, since the study was performed in a naturalistic 
setting, which is the ideal way to demonstrate the results of an effectiveness study.  
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CONCLUSIONS 
 
Omalizumab allowed a statistically significant decrease in the percentage of eosinophils 
in induced sputum of this cohort of patients. Although very sensible, NO is a less 
reproducible and thus less reliable method to evaluate chronic airway inflammation in a 
paediatric allergic population with uncontrolled severe asthma. Induced sputum seems 
to be a better method to monitor chronic inflammation and thus the response to chronic 
omalizumab treatment while NO measurement would be more useful to monitor acute 
events preceding exacerbations. 
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